Demars Financial Group LLC Acquires New Holdings in Novo Nordisk A/S $NVO

Demars Financial Group LLC bought a new position in Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 16,339 shares of the company’s stock, valued at approximately $907,000.

Several other large investors also recently added to or reduced their stakes in the business. True Wealth Design LLC raised its holdings in shares of Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares in the last quarter. NewSquare Capital LLC increased its position in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after buying an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. acquired a new position in Novo Nordisk A/S during the second quarter worth $37,000. Maseco LLP bought a new position in Novo Nordisk A/S during the second quarter valued at about $39,000. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Novo Nordisk A/S in the third quarter worth about $39,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Down 2.6%

NVO opened at $60.70 on Wednesday. The business has a 50 day moving average of $51.41 and a 200-day moving average of $54.76. The stock has a market capitalization of $271.00 billion, a price-to-earnings ratio of 17.64 and a beta of 0.66. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The firm had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Ratings Changes

NVO has been the subject of several recent analyst reports. CICC Research assumed coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They set an “outperform” rating and a $73.50 price target for the company. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. HSBC reissued a “hold” rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a report on Wednesday, January 14th. Finally, Hsbc Global Res downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $56.21.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.